Ozempic-Like Drugs May Hold Risks For Surgical Patients, Officials Say
Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Ozempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Health and Me on MSN2h
GLP-1 Drugs Affect 175 Health Conditions, Benefits Heart But Pose Risk To Kidneys
A new study has examined the effects of GLP-1 drugs on 175 different health outcomes. ​​​While these drugs have been found to ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Why Weight-Loss Drugs Could Be Game-Changers for Your Investment Portfolio
Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.
Citigroup Issues Pessimistic Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price
Eli Lilly and Company (NYSE:LLY – Get Free Report) had its target price lowered by equities researchers at Citigroup from ...
Consumer Cos Up on Strong Earnings — Consumer Roundup
Consumer companies rose amid generally strong earnings. Southwest Airlines posted a profit in the fourth quarter as bookings during the holidays were better than expected on the back of travel demand ...